Neurosoft Bioelectronics develops a platform of minimally invasive brain-computer interfaces intended to access the full cortex without penetrating brain tissue using proprietary soft and stretchable electrodes. The company’s technology is engineered to be significantly more compliant than conventional neural interfaces to enable broader cortical coverage via minimally invasive procedures. Neurosoft has tested its devices in 10 patients across two ongoing clinical trials at UTHealth Houston and UMC Utrecht, including a 64-channel soft brain interface study for epilepsy surgery guidance. Its IP and scientific footprint include more than 25 patents and over 25 peer-reviewed publications. The firm aims to build a large-scale neural data platform to support foundation models of the human cortex and to improve performance of invasive and non-invasive BCIs. With over $20 million raised to date, Neurosoft plans to use new funding to advance clinical demonstrations and move toward U.S. commercialization of its first brain interface product.

Total raised

$8M

Funding rounds

2

Latest round

Seed

Latest activity

May 2026